Latest news with #KoreaUniversity
Business Upturn
21 hours ago
- Business
- Business Upturn
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: Processing 1,000+ samples per week per instrument Requiring only a single mass spectrometry injection per sample Completing 80-sample batches with <5 hours automated runtime Identifying up to 10 times more proteins than conventional mass spectrometry methods 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact: Consort Partners [email protected] Investor Contact: Carrie Mendivil [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Associated Press
a day ago
- Health
- Associated Press
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact: Consort Partners [email protected] Investor Contact: Carrie Mendivil [email protected]
Yahoo
a day ago
- Health
- Yahoo
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: Processing 1,000+ samples per week per instrument Requiring only a single mass spectrometry injection per sample Completing 80-sample batches with <5 hours automated runtime Identifying up to 10 times more proteins than conventional mass spectrometry methods 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact:Consort Partnerspr@ Investor Contact:Carrie Mendivilinvestor@ in to access your portfolio
Korea Herald
4 days ago
- Business
- Korea Herald
Korea University opens doors to Harvard international students blocked by Trump's crackdown
Korea University has announced plans to welcome professors, researchers and students from Harvard University following a move by the Trump administration to revoke the enrollment of international students at Harvard. The university is the first in South Korea to formally step forward with an offer of support for those affected. Korea University, one of the country's most prestigious educational institutions, said it would launch a special program to assist Harvard-affiliated international professors, postdoctoral researchers, graduate students and undergraduates who are facing uncertainty due to the US government's restriction on foreign student enrollment. Under the initiative, undergraduate and graduate students will be able to continue their studies at Korea University through transfer admissions or exchange programs. The university also pledged to ensure that credits earned could be transferred when students return to Harvard. The university seeks to appoint distinguished international faculty, including scholars from Harvard, as visiting professors with support such as housing and relocation assistance. 'In times like these, we must ensure that the next generation of scholars can continue their academic journeys without disruption,' said Kim Dong-won, president of Korea University. 'We will do all we can to support talented individuals whose education and research have been jeopardized.' The Trump administration formally notified Harvard University that its Student and Exchange Visitor Program certification had been revoked on May 22, barring the university from hosting international students on F-1 or J-1 visas. However, a US court issued a temporary injunction the next day, allowing affected students and researchers to retain their visa status while legal proceedings are underway.
Cision Canada
6 days ago
- Business
- Cision Canada
MEXC Ventures at the Forefront of Korea's Blockchain-AI University Innovation Showcase
SEOUL, South Korea , May 27, 2025 /CNW/ -- MEXC Ventures proudly served as a key sponsor of the 2025 Korea University Blockchain Startup Ideathon, held on May 16 at Korea University's Hana Square. Co-located with the National Center of Excellence in SW AI Startup Ideathon, organized under the National Program of Excellence in Software Universities, which includes 48 universities such as Korea University, Hanshin University, KAIST and Yonsei University, the event showcased emerging ideas in blockchain and artificial intelligence from students and early-stage entrepreneurs across Korea. Hosted by Korea University's College of Informatics and jointly organized with the KU Blockchain Research Institute and TokenPost, the blockchain track received 27 team submissions, from which 10 teams were selected through a competitive preliminary review to advance to the final round. Similarly, the AI track saw 36 entries, with 10 finalists selected. Across both tracks, 208 participants registered for the competition. On the day of the final presentations, over 600 attendees—including students, faculty, industry professionals, and investors—gathered to experience the culmination of this large-scale university-driven ideathon. MEXC Ventures served as a premier sponsor of the blockchain track, alongside the Korea Internet & Security Agency (KISA), LG CNS, and Tether. The AI track, organized under the same program, was supported by Koscom and Toss, contributing to a diverse and collaborative innovation ecosystem across both domains. As part of its sponsorship, MEXC Ventures presented the "MEXC Ventures Award" to the team AlchemyLab in recognition of their creativity and potential in decentralized applications. The blockchain track featured several distinguished awards, including the President of KISA Award (Pondmakers), Dean of Korea University College of Informatics Award (ArcSync), and the KU Blockchain Research Institute Award (IPSHOP). Other industry-sponsored recognitions included the Tether Award (Nestyle), along with special prizes for innovation (Q-medicine), convergence (TokenSquare), and creativity (EyeOfTime). Tracy Jin, COO of MEXC Ventures, joined the event as a keynote speaker, delivering a session titled "Catching the Next Wave: How Blockchain and AI Are Shaping Startup Innovation." In her remarks, Jin emphasized: "Today's students aren't just learning — they're building. This new generation is deeply connected to what comes next in technology. Events like this show how universities can be the launchpads for real change, and we're proud to stand alongside Korea University in supporting this movement." The judging panel for the blockchain track included Seolbin Choi, representing MEXC Ventures, alongside respected figures from Koscom, LG CNS, Kim & Chang, and Toss. This event marks MEXC Ventures' first official university-backed blockchain engagement in Korea. The company reaffirmed its commitment to further supporting Korea's blockchain talent pipeline and strengthening bridges between academia and the Web3 ecosystem. In parallel with the ideathon, MEXC Ventures also organized AI x Web3 Connect at the Hana Square Exhibition Hall on the same day. Co-organized with the KU Blockchain Research Institute, the exhibition brought together major players in the AI and blockchain ecosystem for a day of hands-on demos, startup showcases, and industry networking. Projects and companies such as Tether, OKX Wallet, and Avalanche participated in the exhibition, further enriching the event's technical depth and global relevance. About MEXC Ventures MEXC Ventures is dedicated to accelerating blockchain and web3 innovation through investment, project incubation, and strategic partnerships. With the philosophy of "Empowering Partners and Growing Together," MEXC Ventures provides founders with capital, resources, and global network access to help scale their ideas into impactful businesses. Visit MEXC Ventures.
